57 results about "Piracetam" patented technology

The invention discloses a new synthesizing technique of chiral drug (S)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide ( left Piracetam) intermediate (S)-(+)-2-aminobutanamide hydrochlorate, which comprises the following steps: adopting 2-brobutyrate as initial raw material; aminating; esterifying; ammonolyzing; detaching; looping; obtaining the object compound; making mixed rotary free alkaline (+-)-2-aminobutanamide; adopting half-quantum resolution method to connect chemical detaching salt to evolve salt; removing the detaching agent through alkalization; obtaining the (S)-(+)-2-aminobutanamide hydrochlorate with optical activity; using the mother liquor to make the product. The invention improves the receiving rate and saves the cost of raw material with simply technical operation and low cost, which resolves the resolved mother liquor after racemic action again to reduce the pollution of environment, therefore fitting for industrialized manufacturing.

The invention belongs to an oral Chinese herbal preparation for treating post-traumatic brain syndrome, and the oral Chinese herbal preparation is a human medicinal product. The preparation is prepared from the following Chinese herbs in parts by weight: 10+/-2 parts of Astragalus mongholicus, 10+/-2 parts of American ginseng, 10+/-2 parts of Angelica sinensis, 10+/-2 parts of medlar, 10+/-2 parts of the root of red-rooted salvia, 10+/-2 parts of ligusticum wallichii, 10+/-2 parts of root of common peony, 10+/-2 parts of peach kernel, 10+/-2 parts of Poria cocos, 10+/-2 parts of pericarpium citri reticulatae, 10+/-2 parts of plantain seed, 10+/-2 parts of tabasheer, 10+/-2 parts of rhizoma acori graminei, 10+/-2 parts of gastrodia elata, 10+/-2 parts of uncaria, 10+/-2 parts of spina date seed, 10+/-2 parts of amber powder and 6+/-1.2 parts of honey-fried licorice root. Clinical effect observation proves that the total effective rate of the oral Chinese herbal preparation to the oral traditional Chinese medicine preparation is 94.07%, and has better treatment effect (P<0.01) compared with Western medicines such as Rotundine, piracetam, oryzanol and nimodipine for treating post-traumatic brain syndrome. Moreover, the Chinese herbal preparation has no obvious toxic or side effect, and can be taken for a long time. The dose of the preparation is small, and effective medicinal components are easy to release, can be absorbed quickly and can fully play the pharmaceutical effect. The preparation is convenient to carry, easy to take and beneficial to large-scale production.

This invention relates to the medicinal composition for prevention and cure of intracranial hypertension, which contains piracetam (1-acetamido-2ketone-pyrrolidine) and the carrier tolerable to pharmaceutics. It can further contain osmotic diuretic such as mannitol,etc.; or anti-tissue exuedative medicine such as esculin sodium; or the medicine such as nitroglycerin, sodium nitroprusside, etc. used for resulting in controllable hypotension.

The present invention is Piractetam medicine composition with the function of promoting thinking and memory and its preparation process. The composition consists of Piracetam and reductive glutathione in the weight ratio of 10-100 to 6-12 as well as pharmaceutically acceptable supplementary material. It has high curative effect, high stability, less adverse reaction and high safety.

The invention relates to the purpose of Levetiracetam during the process of preparing galangal medicine, the Levetiracetam is anti-epilepsia medicine with good curative effect at present, because the Levetiracetam and the structure of the naoyizhi medicine piracetam have large similarity, the invention aims at exploring the function of the Levetiracetam on the aspect of Naoyizhi. The invention is to find out therapeutic medicine with more obvious, safer and more reliable curative effect for intelligence damage caused by a cerebrovascular disease. The normal taking dosage of the Levetiracetam is 500 to 1500 mg/time. 2 to 3 times for one day, the Levetiracetam and auxiliary materials which can be accepted on the pharmacy can be produced into oral tablets, capsules and pelletized granules.

The invention belongs to the technical field of a pharmaceutical co-crystal, and particularly relates to a novel febuxostat pharmaceutical co-crystal and a preparation method thereof. The space group of piracetam pharmaceutical co-crystal prepared by the invention is a monoclinic system, one isonicotinic acid molecule and two febuxostat molecules are combined together through a hydrogen bond respectively to form a basic structural unit of the febuxostat pharmaceutical co-crystal. A solvent selected in a preparation process of pharmaceutical co-crystal is ethyl acetate, and a solvent room temperature volatilization method is adopted. Due to a relatively low boiling point of the selected organic solvent, crystal is separated out during the process of solvent volatilization. The pharmaceutical co-crystal prepared by the invention inherits characteristics of traditional medicaments in preparing hyperuricemia of gout patients, and also has obvious change on solubility, stability and bioavailability.

The invention provides a preparation method for cerebroprotein hydrolysate in piracetam cerebroprotein hydrolysate tablets. The cerebroprotein hydrolysate is extracted from brain tissues of mammals except for human being and contains specific polypeptide and various amino acids including free lysine and free glutamic acid, and molecular weight of all compositions is below 5,000-10,000 daltons. The weight proportion of polypeptide to free lysine to free glutamic acid in the cerebroprotein hydrolysate is (1-200):(0.1-100):(0.1-80). According to the invention, the pharmaceutical composition contains active substances capable of treating cranial vascular disease and cerebral metabolism disorder sequela caused thereby, the active substances can regulate and improve cerebral metabolism. After determination, the content of amino nitrogen in the cerebroprotein hydrolysate achieves 40-50 percent of total nitrogen content, so that the cerebroprotein hydrolysate can be used for preparing compound piracetam cerebroprotein hydrolysate tablets.

The invention relates to a usage of levetiracetam in preparing a medicine helpful for intelligence. Levetiracetam is a good medicine in curing epilepsy at present. Due to the great similarity in terms of structure with piracetam which is helpful for intelligence, the invention aims to further discover the function of levetiracetam in improving the intelligence, and to provide a medicine which is safer and more remarkable and reliable in curing the intelligence damage caused by cerebrovascular diseases. The normal dose of levetiracetam is 500mg to 1500mg at one time, two times per day. Levetiracetam can be made into orally taken troches, capsules and grains, together with accessories medically acceptable.

The invention belongs to the field of chemical synthesis and relates to a synthesis method of piracetam. The method comprises the following steps: by taking alpha-pyrrolidone as raw material, slowly dropwise adding a methanol solution (28.4% w/w) of sodium methoxide at reduced pressure; distilling the methanol solvent at reduced pressure and normal pressure; after methanol is evaporated completely, slowly dropwise adding a methylbenzene solution of methyl chloroacetate, controlling the reaction temperature to be 20 to 110 DEG C and reacting for 5.0 hours under heat-preserved condition; cooling to room temperature; carrying out suction filtering; distilling the filtrate at reduced pressure; collecting fractions with the temperature of 100 to 105 DEG C; mixing the fractions with ammonia gas/a methanol solution; reacting at the temperature of 50 to 70 DEG C for 3-18 hours; thermally filtering to obtain a primary crude product; concentrating the filtrate at reduced pressure to obtain a secondary crude product; mixing the crude products; recrystallizing by using an alcohol solvent; filtering and drying to obtain white crystals to obtain piracetam, wherein the mole ratio of alpha-pyrrolidone to methyl chloroacetate is 1:(1.0-2.0). The method is mild in reaction condition, simple and convenient in production and operation; synthesis raw materials and solvents are cheap and easily available, and therefore the method is suitable for large-scale industrial production; after the recrystallization, the yield is as high as 82.4% (metered based on the alpha-pyrrolidone), and the purity is higher than 99.9%.

The invention relates to an effervescent tablet containing piracetam, which comprises piracetam, citric acids, sodium bicarbonates, oligosaccharides or other edible sugars, and the weight ratio of the piracetam to the citric acid to the sodium bicarbonate to the oligosaccharide or other edible sugars is (10 to 20): 30: 7: 200. The effervescent tablet in the invention has the advantages that the piracetam used as a functional composition is prepared into the effervescent tablet, therefore, compared with other medicament forms, the piracetam-containing effervescent tablet has the advantages of good stability, easy absorption, good taste, and capability of being directly soaked in water for drinking without mixing, and is easy to keep and dissolve.

The invention belongs to the technical field of pharmaceutical co-crystals, and particularly relates to a piracetam pharmaceutical co-crystal taking 3,4-dihydroxy-benzoic acid as a precursor and a preparation method of the piracetam pharmaceutical co-crystal. A space group of the pharmaceutical co-crystal is a monoclinic system, and three 3,4-dihydroxy-benzoic acid molecules (1) and a piracetam molecule (2) are combined through hydrogen bonds to form a basic structural unit of the piracetam pharmaceutical co-crystal. In a pharmaceutical co-crystal preparation process, a selected solvent is methanol; an adopted method is a solvent room-temperature volatilization method; and as a boiling point of the selected organic solvent is lower, a crystal is precipitated in a solvent volatilization process. The prepared pharmaceutical co-crystal inherits the characteristic of the traditional bulk pharmaceutical for repairing nerve cells of a brain function injured patient, and the dissolvability, the stability and the bioavailability of the pharmaceutical co-crystal are improved obviously.

The invention belongs to the technical field of drug co-crystals and in particular relates to a novel piracetam drug co-crystal and a preparation method thereof. An N atom on an amino group in one piracetam molecule is taken as a hydrogen bond donor, an O atom on a p-hydroxybenzoic acid carboxyl is taken as a hydrogen bond acceptor, and the N atom and the O atom form a basic structural unit of the piracetam co-crystal by forming hydrogen bonds. The preparation method of the piracetam drug co-crystal is a solvent room temperature volatilization method. The drug co-crystal prepared by the invention inherits the characteristic of the traditional bulk drug of treating cerebral injury and cerebrovascular diseases, and is obviously improved in the aspects of dissolubility, stability and bioavailability.

The invention belongs to the field of biological agents, and relates to cerebroprotein hydrolysate in piracetam and cerebroprotein hydrolysate tablets and a preparation method of the cerebroprotein hydrolysate, in particular to cerebroprotein hydrolysate which is extracted from brain tissues of mammals excluding human and contains polypeptide and multiple amino acids including free amino acids and free glutamic acid, as well as a preparation method of the cerebroprotein hydrolysate. The provided method comprises steps such as homogenate, two times of degreasing of acetone, enzymolysis of trypsin and pepsin and the like. The content of amino acids in the cerebroprotein hydrolysate prepared with the method is remarkably higher than that in the prior art.

The invention belongs to the technical field of medicines and discloses a piracetam cerebroprotein hydrolysate dropping pill and a preparation method thereof. The dropping pill comprises active ingredients and a substrate, wherein the active ingredients are composed of piracetam, cerebroprotein hydrolysate, and the like. The prescription of the dropping pill provided by the invention is confirmed according to a scientific screening test. A pharmacologic test proves that the dropping pill provided by the invention has better pharmacologic effect than that of the marketed preparation taking compound piracetam and cerebroprotein hydrolysate as raw materials.

A high-energy composite medicine for treating acute or chronic cerebrovascular disease, cerebral trauma, toxipathic cerebrosis, hypomneis and cerebral disfunction contains proportionally inosine, ATP, VC and piracetam.

The invention belongs to the field of medication and particularly relates to an eye drop for treatment of nearsightedness and a preparation method of the eye drop. The eye drop comprises, by weight, 5-15 parts of silkworm larva, 5-15 parts of caulis dendrobii powder, 70-79 parts of fructus ligustri lucidi, 90-100 parts of semen cassiae, 50-80 parts of Vitamin B1, 50-70 parts of Vitamin C, 5-15 parts of borneol, 5-15 parts of mouse nerve growth factors, 50-80 parts of Vitamin B12, 5-15 parts of sodium chloride and 60-80 parts of piracetam. By the arrangement, problems that drug therapy is proneto side effects, defects prone to recurrence, risks and sequelae of surgical treatment and wearing optical glasses can only overcome the shortcoming of daily vision of patients with visual impairmentbut not the root cause are solved, and the eye drop adopts natural raw materials is developed into a safe, efficient and high-quality product with reasonable compatibility and synergistic effect, remarkable effect in the treatment of nearsightedness and safety and efficiency.

The present invention provides a method of treating apathy syndrome in a human subject. The human subject is first evaluated to determine whether one or more behavioral characteristics of apathy are observed. If such characteristics are observed, the subject is treated with a 2-oxopyrrolidine compound, such as nefiracetam, piracetam, aniracetam, pramiracetam, nebracetam, fasoracetam, levetiracetam, or oxiracetam, in an amount effective to produce an improvement in such apathy characteristics. The present invention is useful in treating apathy in a subject suffering from conditions associated with or characterized by frontal-subcortical dysfunction. The present invention is also useful in treating apathy in a subject suffering from a stroke, Alzheimer's disease, Parkinson's disease, traumatic brain injury, depression, schizophrenia, chronic hepatitis C infection, or HIV infection.